Mastodon

Mycospor® (Solution, Cream) Instructions for Use

ATC Code

D01AC10 (Bifonazole)

Active Substance

Bifonazole (Rec.INN registered by WHO)

Clinical-Pharmacological Group

External antifungal drug

Pharmacotherapeutic Group

Antifungal agent

Pharmacological Action

Broad-spectrum antifungal agent, an imidazole derivative.

The mechanism of action is associated with the disruption of ergosterol synthesis, which is a component of the fungal cell membrane, leading to a change in its structure and properties.

It is active against dermatophytes, yeasts (including the genus Candida), molds, and other types of fungi (Malassezia furfur).

It also shows activity against Corynebacterium minutissimum.

Pharmacokinetics

It penetrates well into the affected layers of the skin.

Absorption is 0.6-0.8%, and the concentration in blood plasma is not detectable.

Six hours after application, the concentration in the skin reaches or many times exceeds the minimum effective concentration for the main fungi causing dermatomycoses.

It is detected in the skin for 36-48 hours.

Indications

Treatment of fungal diseases caused by microorganisms sensitive to bifonazole: microsporia, trichophytosis of smooth skin and scalp, favus, rubrophytosis, mycoses of feet and hands, onychomycosis, tinea cruris, pityriasis versicolor, erythrasma, superficial skin candidiasis, candidiasis of nail folds, nails, genitals; interdigital intertrigo, foot hyperhidrosis.

ICD codes

ICD-10 code Indication
B35.0 Mycosis of beard and head
B35.1 Onychomycosis
B35.2 Mycosis of hands
B35.3 Tinea pedis
B35.4 Tinea corporis
B35.6 Tinea cruris
B35.8 Other dermatophytoses
B36.0 Pityriasis versicolor
B37.2 Candidiasis of skin and nails
B37.3 Candidiasis of vulva and vagina
B37.4 Candidiasis of other urogenital sites
L08.1 Erythrasma
N51.2 Balanitis in diseases classified elsewhere
N77.1 Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere
R61.0 Localized hyperhidrosis
ICD-11 code Indication
1C44 Non-pyogenic bacterial infections of skin
1F23.10 Candidiasis of vulva and vagina
1F23.11 Candidal balanoposthitis
1F23.1Z Candidiasis of skin or mucous membranes, unspecified
1F28.1 Dermatophytic onychomycosis
1F28.2 Dermatophytosis of foot
1F28.3 Genitofemoral dermatophytosis
1F28.Y Other specified dermatophytosis
1F28.Z Dermatophytosis, unspecified
1F2D.0 Pityriasis versicolor
1F65 Enterobiasis
1H0Z Unspecified infection
EE00.0Z Localized hyperhidrosis, unspecified
GB06.0Z Unspecified balanoposthitis
1A94.0 Genital or urogenital tract infection caused by Herpes simplex virus
GA41 Ulcerative or erosive diseases of vulva
1F23.1Z Candidiasis of skin or mucous membranes, unspecified
XA5FG3 Genital region

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Apply a thin layer of the cream or a few drops of the solution to the affected and surrounding skin areas once daily.

Administer the product preferably in the evening before bedtime. Gently rub it in until fully absorbed.

For skin infections, including tinea pedis, tinea cruris, and cutaneous candidiasis, the typical treatment duration is 2 to 4 weeks.

For pityriasis versicolor, continue treatment for 1 to 2 weeks.

For erythrasma, the usual treatment period is 2 to 3 weeks.

In cases of onychomycosis, apply the formulation daily under occlusive dressing until the nail regrows completely. This process may require several months.

Continue application for at least two weeks after the clinical symptoms have completely resolved to prevent relapse.

If no improvement is observed after 3 to 4 weeks of treatment, re-establish the diagnosis.

Avoid contact with the eyes, mucous membranes, and open wounds.

Wash hands thoroughly before and after each application.

Adverse Reactions

Local reactions rarely – slight redness, skin irritation, burning and tingling sensation.

When treating fungal nail diseases, reactions at the edges or on the nail bed are possible (irritation, redness, maceration, peeling, contact dermatitis).

Allergic reactions are possible in predisposed patients.

Contraindications

Hypersensitivity to bifonazole.

Use in Pregnancy and Lactation

Use in the first trimester of pregnancy is possible only for strict indications.

Pediatric Use

Use in infants should be done with caution, under medical supervision.

Special Precautions

Use in infants should be under medical supervision.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Bayer, AG (Germany)

Manufactured By

Kern Pharma S.L. (Spain)

Dosage Form

Bottle OTC Icon Mycospor® Cream for external use 1%: tube 15 g

Dosage Form, Packaging, and Composition

Cream for external use homogeneous, white in color.

100 g
Bifonazole (micronized) 1 g

Excipients : benzyl alcohol – 2 g, cetearyl alcohol (cetyl alcohol 60%, stearyl alcohol 40%) – 10 g, cetyl palmitate – 3 g, octyldodecanol – 13.5 g, polysorbate 60 – 1.5 g, sorbitan stearate – 2 g, purified water – up to 100 g.

15 g – aluminum tubes (1) – cardboard packs.

Marketing Authorization Holder

Bayer, AG (Germany)

Manufactured By

KVP Pharma + Veterinar Produkte, GmbH (Germany)

Dosage Form

Bottle OTC Icon Mycospor® Solution for external use 1%: bottle 15 ml with dropper

Dosage Form, Packaging, and Composition

Solution for external use transparent, from colorless to light yellow in color.

100 ml
Bifonazole 1 g

Excipients : ethanol (ethyl alcohol) 96% – 30 g, isopropyl myristate – 52.6 g.

15 ml – dark glass bottles (1) with a dropper – cardboard packs.

TABLE OF CONTENTS